Neumora Therapeutics Gross Profit

The latest gross profit for NMRA is $-5M as of June 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $740M. Investors often review this figure alongside Neumora Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMRA's gross profit moved from $0 to $-5M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neumora Therapeutics's operating scale or balance-sheet position.

Against its sector companies, NMRA currently prints $-5M for gross profit, while the sector average sits near $740M. That is roughly 100.7% below the sector mean. Large gaps often invite a closer look at Neumora Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $-5M for NMRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $740M. Explore the charts below for those layers of context.

After noting NMRA's gross profit ($-5M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.